Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona.
The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The next trial, Divelbliss v. C.R. Bard, is scheduled to begin on August 18, 2026. It involves an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases. Infection-only claims may face harder causation arguments and could receive lower settlement offers if Bard eventually proposes a global resolution.
This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim. No global settlement has been announced, and all payout estimates remain speculative.












